EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Type 1 and type 2 torpedo maculopathy

Annekatrin Rickmann, Jan-Philipp Bodenbender, Faik Gelisken, Laura Kühlewein

Graefe's Archive for Clinical and Experimental Ophthalmology · 2024-06 · 262 (6) · 1805-1810

DOI: 10.1007/s00417-024-06386-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Graefe's Archive for Clinical and Experimental Ophthalmology, online erschienen am 30.01.2024. Verfasst von Annekatrin Rickmann und 3 weiteren Autor:innen. Beteiligte Einrichtung: Knappschaft Hospital Saar, Department for Ophthalmology, Sulzbach, Germany. Hauptthemen laut MEDLINE: Tomography, Optical Coherence, Fluorescein Angiography, Retinal Pigment Epithelium, Visual Acuity. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eberhard Karls Universität Tübingen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To analyze torpedo maculopathy (TM) and to report the characteristics of the disease.

Methods

Retrospective study. The review of a database for clinical diagnosis identified eight patients with TM lesions in the retina between 2016 and 2022. Multimodal imaging was used to analyze the cases.

Results

All cases were unilateral, asymptomatic, and hypopigmented. They were associated by surrounding hyperpigmented retinal pigment epithelium changes to varying degrees. All lesions were located in the temporal retina on the horizontal axis, pointing towards the fovea, except for one patient with a lesion inferior to the fovea. Optical coherence tomography imaging revealed a normal inner retina in all eyes. In the area of the TM lesion, attenuation of the interdigitation zone was seen in mild cases (three cases). All other five patients had thinning of the outer nuclear layer and loss of ellipsoid zone and interdigitation zone of the TM lesion. Four of these cases had a subretinal cavitation/cleft, and two of them additionally an inner choroidal excavation. No patient had any sign of choroidal neovascularization. The average age for patients with type 1 TM was 18 years and for type 2 TM 16.5 years.

Conclusion

In this large case series, we could not detect an age difference between the different types of the TM. Contrary to previous discussions, type 2 TM can also occur in young patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tomography, Optical CoherenceFluorescein AngiographyRetinal Pigment EpitheliumVisual AcuityFundus OculiRetinal DiseasesHumansRetrospective StudiesMaleFemaleAdolescentAdultYoung AdultChildMacula LuteaMultimodal ImagingFollow-Up Studies

Stichwörter der Autor:innen

Choroidal excavationFundus autofluorescenceOptical coherence tomographyTorpedo maculopathyTorpedo retinopathy

Autor:innen und Institutionen

  • Knappschaft Hospital Saar, Department for Ophthalmology, Sulzbach, Germany.
  • University Eye Hospital, Department for Ophthalmology, Eberhard Karls University, Tübingen, Germany.
  • University Eye Hospital, Department for Ophthalmology, Eberhard Karls University, Tübingen, Germany. Laura.Kuehlewein@med.uni-tuebingen.de.

Förderung

  • Eberhard Karls Universität Tübingen

Zitieren

APA

Rickmann, A., Bodenbender, J. P., Gelisken, F., & Kühlewein, L. (2024). Type 1 and type 2 torpedo maculopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 262(6), 1805-1810. https://doi.org/10.1007/s00417-024-06386-0

Vancouver

Rickmann A, Bodenbender JP, Gelisken F, Kühlewein L. Type 1 and type 2 torpedo maculopathy. Graefe's Archive for Clinical and Experimental Ophthalmology. 2024;262(6):1805-1810. doi:10.1007/s00417-024-06386-0

BibTeX
@article{Rickmann2024,
  author = {Rickmann, Annekatrin and Bodenbender, Jan-Philipp and Gelisken, Faik and Kühlewein, Laura},
  title = {Type 1 and type 2 torpedo maculopathy},
  journal = {Graefe's Archive for Clinical and Experimental Ophthalmology},
  year = {2024},
  volume = {262},
  number = {6},
  pages = {1805--1810},
  doi = {10.1007/s00417-024-06386-0}
}
Kostenlos starten →